SECsense Logo

BioLineRx Ltd. Reports $1.6M Capital Raise in January 2025 - Form 6-K Filing

$BLRX
Form 6-K
Filed on: 2025-01-06
Source
BioLineRx Ltd. Reports $1.6M Capital Raise in January 2025 - Form 6-K Filing

Here are the key insights extracted from the provided section of the financial report (Form 6-K) for BioLineRx Ltd.:

  1. Filing Details:
  • Type: Form 6-K
  • Commission File Number: 001-35223
  • Filing Date: January 6, 2025
  1. Company Information:
  • Company Name: BioLineRx Ltd.
  • Address: 2 HaMa’ayan Street, Modi’in 7177871, Israel
  1. Reporting Period:
  • The report pertains to activities for the month of January 2025.
  1. Capital Raise:
  • During January 2025, BioLineRx Ltd. successfully sold a total of 5,676,396 American Depositary Shares (ADS).
  • Each ADS represents 15 ordinary shares with a par value of NIS 0.10 per share.
  • The total gross proceeds from this sale amounted to approximately $1.6 million.
  • The sales were executed through the company's "at-the-market" equity offering program, with H.C. Wainwright & Co., LLC acting as the sales agent.
  1. Legal Compliance:
  • The report and the attached press release are incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.
  1. Signature:
  • The report was signed by Philip A. Serlin, Chief Executive Officer of BioLineRx Ltd.

These elements highlight the company's recent fundraising activities and regulatory compliance, which are crucial for investors and stakeholders monitoring the company's financial health and operational strategies.